The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | The emerging role of liquid biopsies for gastrointestinal malignancies
Benedikt Westphalen, MD, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany, comments on the current state of liquid biopsies for gastrointestinal cancers. Whilst questions remain regarding the precise timing of their use in the clinic, there is emerging evidence that they are beneficial in detecting genomic alterations. There is additional evidence that adjuvant chemotherapy can now be administered based on minimal residual disease (MRD) status in patients with colorectal cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
